Literature DB >> 12030915

Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.

C Rolf1, U Knie, G Lemmnitz, E Nieschlag.   

Abstract

OBJECTIVE: Transdermal testosterone gel treatment is an effective androgen substitution therapy with several advantages over conventional substitution therapies. Whereas side-effects due to overdosing of hypogonadal patients are unlikely, testosterone gel application without protection may cause severe side-effects in other subjects (partners, family members) by contamination. Therefore, the risk of testosterone transfer of a newly developed 2.5% testosterone gel preparation was evaluated.
DESIGN: In two clinical randomized open single-centre studies on healthy male volunteers the percentage of testosterone remaining on the skin after gel application over time (n = 12) and the possibility of a transfer of testosterone to another person (n = 28) was evaluated. In the second study the endogenous testosterone production in the receiving subjects was suppressed by injecting 400 mg norethisterone enanthate (NETE).
RESULTS: After 8 h approximately 60% of testosterone applied to the skin could be recovered. When the skin had been previously washed with water, only about 14% of applied testosterone could be recovered. After intense skin contact with a volunteer who had applied testosterone before on his forearm, no increase in testosterone serum levels could be found in NETE-suppressed men.
CONCLUSION: Although considerable amounts of testosterone remain on the intact skin for several hours after evaporation of the alcohol vehicle, contamination of a second, especially female or prepubertal, subject causing side-effects seems very unlikely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030915     DOI: 10.1046/j.1365-2265.2002.01529.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Testosterone hormone replacement therapy: state-of-the-art and emerging technologies.

Authors:  Marie-Laure Leichtnam; Hervé Rolland; Patrick Wüthrich; Richard H Guy
Journal:  Pharm Res       Date:  2006-06-09       Impact factor: 4.200

Review 2.  [Hypogonadism in the elderly man. Reliable diagnosis and therapy].

Authors:  M Zitzmann; E Nieschlag
Journal:  Internist (Berl)       Date:  2003-10       Impact factor: 0.743

Review 3.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Transdermal testosterone delivery: testosterone patch and gel.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  World J Urol       Date:  2003-10-09       Impact factor: 4.226

Review 5.  Testosterone replacement therapy in male hypogonadism.

Authors:  M Byrne; E Nieschlag
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

6.  An interesting cause of hyperandrogenemic hirsutism.

Authors:  Murat Atmaca; İsmet Seven; Rıfkı Üçler; Murat Alay; Veysi Barut; Yaren Dirik; Yasin Sezgin
Journal:  Case Rep Endocrinol       Date:  2014-12-16

Review 7.  Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.

Authors:  A M Isidori; G Balercia; A E Calogero; G Corona; A Ferlin; S Francavilla; D Santi; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-11-11       Impact factor: 4.256

Review 8.  Testosterone depot injection in male hypogonadism: a critical appraisal.

Authors:  Aksam A Yassin; Mohamed Haffejee
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

Review 9.  Diagnosis and management of testosterone deficiency.

Authors:  James A McBride; Culley C Carson; Robert M Coward
Journal:  Asian J Androl       Date:  2015 Mar-Apr       Impact factor: 3.285

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.